Recruiting
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
About this study
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to peripheral neuropathy.
- Condition
- Breast Carcinoma, Neuropathy
- Tested
- Laboratory Biomarker Analysis
- Sponsor
- National Cancer Institute (NCI)
Who can join
- Age
- Not specified
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 4
- Study condition: Breast Carcinoma, Neuropathy
- European American patients with DNA available and designated case or control
- African American patients with DNA available and designated case or control status
- Patients who developed grade 2-4 for African American (AA) and grade 3-4 for European American (EA) peripheral neuropathy during their treatment with paclitaxel and who did not develop peripheral neuropathy following a full course of treatment with paclitaxel
Where
1 site, 1 recruiting
Eastern Cooperative Oncology Group
Boston, Massachusetts, United States
Potential match only. Final eligibility is determined by the study team.